info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
15
May
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
10
May
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
9
May
CymaBay Names Harish Shantharam Chief Financial Officer
21
Apr
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
17
Apr
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
16
Mar
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
9
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
1
Mar
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
6
Feb
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
30
Jan
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
1
2
3
4
5
6
7
8
9
10
...27
Next >>
Show All
Scroll
